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Lotte-Emilie Boyhus,a Mia Danielsen, a Nina Smidt Bengtson,a Micha Ben Achim
Kunze,b Xavier Kubiak,c Tjerk J. Sminia,a Jacob Hartvig Løper,a Phuong Thu Tran,a
Kresten Lindorﬀ-Larsen, b Søren G. F. Rasmussen,c Jesper Mosolﬀ Mathiesen‡*a
and Daniel Sejer Pedersen ‡*a
A series of Gs protein peptidomimetics were designed and synthesised based on the published X-ray crystal
structure of the active state b2-adrenergic receptor (b2AR) in complex with the Gs protein (PDB 3SN6). We
hypothesised that such peptidomimetics may function as allosteric modulators that target the intracellular
Gs protein binding site of the b2AR. Peptidomimetics were designed to mimic the 15 residue C-terminal a-
helix of the Gs protein and were pre-organised in a helical conformation by (i, i + 4)-stapling using copper
catalysed azide alkyne cycloaddition. Linear and stapled peptidomimetics were analysed by circular
dichroism (CD) and characterised in a membrane-based cAMP accumulation assay and in a bimane
ﬂuorescence assay on puriﬁed b2AR. Several peptidomimetics inhibited agonist isoproterenol (ISO)
induced cAMP formation by lowering the ISO maximal eﬃcacy up to 61%. Moreover, some
peptidomimetics were found to signiﬁcantly decrease the potency of ISO up to 39-fold. In the bimane
ﬂuorescence assay none of the tested peptidomimetics could stabilise an active-like conformation of
b2AR. Overall, the obtained pharmacological data suggest that some of the peptidomimetics may be able
to compete with the native Gs protein for the intracellular binding site to block ISO-induced cAMP
formation, but are unable to stabilise an active-like receptor conformation.Introduction
The importance of G protein-coupled receptors (GPCRs) within
drug discovery is undisputed. It is estimated that >25% of FDA
approved drugs act via GPCRs.1 However, only 27% of non-
olfactory GPCRs are currently targeted by an approved drug
and 15% are currently in clinical trials, leaving 232 non-
olfactory GPCRs that remain entirely unexploited as drug
targets.2 Despite the central importance of GPCRs, we still have
a very rudimentary understanding of the structure and function
of this family of membrane-spanning receptors, particularly
with respect to how GPCRs interact with intracellular proteins
to achieve signal transduction and physiological responses.
GPCR ligands generally bind to the extracellular side of the
receptor and target the orthosteric or allosteric binding sites, or
both as bivalent ligands.3 On the other hand, the intracellulargy, University of Copenhagen, Jagtvej 162,
sund.ku.dk; daniel.pedersen@sund.ku.dk
, Department of Biology, University of
nhagen, Denmark
of Copenhagen, Blegdamsvej 3, 2200
tion (ESI) available. See DOI:
incipal investigators.
hemistry 2018surface of GPCRs has largely been ignored in the development
of allosteric modulators. Such allosteric modulators could
conceivably be designed to target the receptor surface respon-
sible for recruiting intracellular transducers such as the G
proteins and arrestins and thus be useful pharmacological tool
compounds for studying GPCR signal transduction and
possibly provide a new avenue for drug discovery. Moreover,
such compounds could be useful compounds for X-ray crystal-
lography to stabilise GPCRs in their active state conformation,
which is particularly diﬃcult to crystallise due to the high
degree of receptor exibility in the receptor active state.
Recently, Leowitz and co-workers reported the discovery of an
intracellular small molecule-like allosteric modulator for the b2-
adrenergic receptor (b2AR) using a combinatorial approach with
DNA encoded libraries.4 The allosteric ligand was found to bind
to the intracellular surface of the receptor and inhibit both G
protein and arrestin mediated signalling. Kobilka and co-
workers crystallised a closely related analogue of the same
ligand in complex with the b2AR-T4 lysozyme fusion protein
with the orthosteric inverse agonist carazolol bound. The
structure (PDB 5X7D) clearly shows the ligand occupying the G
protein binding pocket.5
Based on recent bio-structural data of active state GPCRs in
complex with GPCR interacting proteins (GIP)6,7 or mimics
thereof8–12 we wondered if it would be possible to rationallyRSC Adv., 2018, 8, 2219–2228 | 2219
RSC Advances Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
9 
Ja
nu
ar
y 
20
18
. D
ow
nl
oa
de
d 
on
 1
0/
24
/2
01
8 
1:
44
:5
8 
PM
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlinedesign peptidomimetics that target the GIP interface. Such
allosteric ligands could be benecial for stabilisation of GPCRs
in various conformational states for structural studies, as
pharmacological tool compounds, and could possibly provide
a new avenue for therapeutic molecules. There have been some
reports in the literature on using proteinogenic peptides as
GPCR ligands. Hamm and co-workers have published several
papers describing that peptides derived from the C-terminus of
various G protein a subunits (Ga) are capable of reducing cAMP
accumulation by blocking G protein coupling.13–15 Moreover,
Scheerer et al. have reported the X-ray crystal structure of
rhodopsin in complex with an 11-mer C-terminal peptide from
the Gt protein.10 More recently, we reported our eﬀorts to
develop a peptidomimetic that mimics the function of nano-
body 80 (Nb80) a well-known allosteric modulator of the b2AR
that binds at the same site of the receptor as the native Gs
protein.9,16
Using the X-ray crystal structure of the b2AR in complex with
the Gs protein (b2AR-Gs) as a template (PDB 3SN6)7 weFig. 1 (a) The native GasCT15 peptide sequences. Red: residues with n
structure of GasCT15 extracted from PDB entry 3SN6, (c) the GasCT15 p
Isoproterenol (ISO) concentration–response curves of cAMP accumulatio
HEK293 cell membranes overexpressing the b2AR. Data represents mea
The known b2AR-interacting nanobody 80 (Nb80) was included for co
contacts determined by MD simulation26 and X-ray crystallography.7 D
contacts involving backbone carbonyls, bold box: cation–p interaction, (e
in 10 mM NaH2PO4 buﬀer, pH 6.0).
2220 | RSC Adv., 2018, 8, 2219–2228embarked on a project to identify such allosteric modulators for
the b2AR by a structure-based design approach.
Results and discussion
Peptidomimetic design
Hamm and co-workers previously reported that a peptide
comprised of the last 12 amino acid residues from the Gas C-
terminus (GasCT12) was capable of inhibiting Gs protein
coupling to the b2AR and increased agonist aﬃnity for the
receptor.15 However, in our hands the corresponding proteino-
genic 15-mer peptide (GasCT15) did not block agonist induced
cAMP formation in b2AR cell membranes, whereas Nb80
signicantly inhibited the maximal eﬃcacy of ISO (Fig. 1c).
Whereas Hamm and co-workers used saponin-permeabilised
C6 glioma cells, all peptides reported herein were evaluated in
HEK293 membranes overexpressing the b2AR.17 We selected to
work in a cell membrane-based assay setup to render the
intracellular surface freely accessible to the ligands and elimi-
nate issues related to cell permeability. Likewise, Rasmusseno or weak receptor contacts. Blue: reverse turn, not helical, (b) the
eptide does not inhibit agonist induced cAMP formation of the b2AR.
n were generated in the absence and presence of 50 mM peptide using
n  SEM from 3–4 independent experiments carried out in duplicates.
mparison at 10 mM.9 (d) Helical wheel projection showing important
ashed boxes: polar contacts involving side chains, solid boxes: polar
) CD spectrum of GasCT15 indicating a random coil structure (at 50 mM
This journal is © The Royal Society of Chemistry 2018
Fig. 2 Stapling positions and unnatural amino acid building blocks.
According to our analysis the red residues represent the best (i, i + 4)-
stapling positions by appropriate substitution with amino acids 1–4
(staples A–C). Staple position D was included to validate the design (a
negative control). To circumvent oxidation problems the norleucine
building block 5was employed as a substitute for methionine (stapling
positions B and D).
Table 1 Synthesis of linear and stapled peptidomimetics. Linear peptides
termini of all peptides were acylated. Peptides 6D–9D were poorly solu
remaining puriﬁed (or crude) linear peptides were stapled by CuAAC and
Linear Amino acid sequence
GasCT15 H-R-D-I-I-Q-R-M-H-L-R-Q-Y-E-L-L-OH
6A Ac-R-D-1-I-Q-R-3-H-L-R-Q-Y-E-L-L-OH
6B Ac-R-D-I-1-Q-R-5-3-L-R-Q-Y-E-L-L-OH
6C Ac-R-D-I-I-Q-R-1-H-L-R-3-Y-E-L-L-OH
6D Ac-R-1-I-I-Q-3-5-H-L-R-Q-Y-E-L-L-OH
7A Ac-R-D-2-I-Q-R-3-H-L-R-Q-Y-E-L-L-OH
7B Ac-R-D-I-2-Q-R-5-3-L-R-Q-Y-E-L-L-OH
7C Ac-R-D-I-I-Q-R-2-H-L-R-3-Y-E-L-L-OH
7D Ac-R-2-I-I-Q-3-5-H-L-R-Q-Y-E-L-L-OH
8A Ac-R-D-1-I-Q-R-4-H-L-R-Q-Y-E-L-L-OH
8B Ac-R-D-I-1-Q-R-5-4-L-R-Q-Y-E-L-L-OH
8C Ac-R-D-I-I-Q-R-1-H-L-R-4-Y-E-L-L-OH
8D Ac-R-1-I-I-Q-4-5-H-L-R-Q-Y-E-L-L-OH
9A Ac-R-D-2-I-Q-R-4-H-L-R-Q-Y-E-L-L-OH
9B Ac-R-D-I-2-Q-R-5-4-L-R-Q-Y-E-L-L-OH
9C Ac-R-D-I-I-Q-R-2-H-L-R-4-Y-E-L-L-OH
9D Ac-R-2-I-I-Q-4-5-H-L-R-Q-Y-E-L-L-OH
a Yield aer preparative HPLC purication to >95% purity (non-NPC corr
being constituted by counter ions and water). Determined by qNMR (see
from crude linear peptide. Overall yield based on resin loading. e Presum
This journal is © The Royal Society of Chemistry 2018
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View Article Onlineet al. were not able to observe any eﬀect of the 20-mer GasCT20
peptide on b2AR receptor function and complex formation with
b2AR.7However, whenGasCT20 was fused to the carboxy terminus
of the b2AR and expressed as a fusion protein a 27-fold increase in
agonist aﬃnity was observed. Based on the results by Rasmussen
et al. we speculate that GasCT20 mainly adopts a random coil
structure in solution rendering binding to the receptor less
favourable. This is consistent with our circular dichroism (CD)
analysis of GasCT15 that showed a random coil structure (Fig. 1e).
Also, the aﬃnity of a linear GasCT peptide for b2AR is likely
signicantly lower than the full Gs protein complex, which has
several additional contacts with the receptor. Based on these
observations, we hypothesised that it would be necessary to
chemically modify the native GasCT15 peptide to improve binding
to the b2AR. In the b2AR-Gs X-ray crystal structure the C-terminus
of Gs adopts an a-helix terminated by a 3-residue reverse turn
(Fig. 1b).7 Thus, we set out to chemically modify GasCT15 to pre-
organise the peptide in a similar conformation. Peptide stapling
is a commonly applied technique for the synthesis of helical
peptides.18–20 Among the many available methods for peptide
stapling we favour CuAAC-stapling between amino acids with
azido- and alkynyl-modied side chains.21,22 This methodology
was originally developed by Tornoe et al.23 and later optimised bywere synthesised on 2-chlorotritylresin preloaded with leucine. The N-
ble in a variety of solvent systems and were not puriﬁed/stapled. The
puriﬁed by preparative RP-HPLC
Stapled Yielda/NPCb (%) Reaction time
NA NA NA
10A 36c/84 15 min
10B 10d/63 Overnighte
10C 10d/45 3 h
NA NA NA
11A 56c/77 15 min
11B 11d/72 Overnighte
11C 26d/71 1 h
NA NA NA
12A 69c/60 1 h
12B 15d/74 1 h
12C 14d/53 2 h
NA NA NA
13A 40c/67 Overnighte
13B 13d/77 Overnighte
13C 11d/60 3 h
NA NA NA
ected). b Net peptide content (NPC) (mass% of peptide, the remainder
ESI for details). c Synthesised from pure linear peptide. d Synthesised
ably nished in <3 hours but le overnight for practical reasons.
RSC Adv., 2018, 8, 2219–2228 | 2221
Fig. 3 CD spectra of linear (blue curves) and corresponding stapled (red curves) peptidomimetics at a concentration of 50 mM (10 mMNaH2PO4
buﬀer, pH 6.0). The ﬁrst row compares stapling at position A (Fig. 2), the second row shows stapling position B and the third row shows
a comparison of stapling positionC. The columns show a comparison of the diﬀerent combinations of stapling residues 1 + 3, 2 + 3, 1 + 4 and 2 +
4, respectively. The helicity of the most helical peptidomimetic 10C as determined by the induced minima at 222 nm and maxima at 190 nmwas
set to 100% and the helicity of all other peptidomimetics were determined relative to that of 10C.
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View Article OnlineCantel et al.24 and has been applied extensively in (i, i + 4)-peptide
stapling in recent years.25
By visual inspection of the b2AR-Gs X-ray crystal structure we
concluded that the 15 C-terminal residues of Gas participate in
important interactions with b2AR. This is consistent with the
conclusions drawn by Hildebrand and co-workers based on MD
simulations.26 In terms of design, it is important that the staple
position does not disrupt binding to the target. By visual
inspection and based on the MD simulation study by Hilde-
brand and co-workers 5 residues were identied as potential
staple anchoring points (Fig. 1). These 5 residues are ideally
positioned for introduction of (i, i + 4)-staples and four stapling
positions would be evaluated in the present study (Fig. 2).
Moreover, four diﬀerent staple designs utilising D- and L-3-azi-
dolysine (1–2), L-propargyl glycine (3) and O-propargylated L-
serine (4) would be explored.
Synthesis
Fmoc-protected propargylglycine (3) is commercially available
and the remaining azide and alkyne modied building blocks
were synthesised in house. Azides 1–2 were synthesised from
the corresponding Fmoc-protected amines as previously re-
ported27 using the diazotransfer reagent imidazole sulfonyl
azide.28,29 Alkyne 4 was synthesised in three steps from Boc-
protected serine according to the published procedure.272222 | RSC Adv., 2018, 8, 2219–2228Finally, for stapling positions B and D commercially available
norleucine (5) was employed as a replacement for the oxidation
prone methionine residue.30 With amino acids 1–5 in hand the
linear peptidomimetics 6–9were synthesised by standard Fmoc-
based solid-phase peptide synthesis (SPPS) on chlorotrityl resin
and the N-terminus was acylated (Table 1). The synthesis of
linear peptides 6–9 A–C was uneventful and they were all puri-
ed by standard preparative RP-HPLC. However, the synthesis
of peptides 6D–9D where two polar residues (D and R) were
replaced proved complicated due to poor solubility aer
cleavage and deprotection. Because peptides 6D–9D were
intended as inactive negative controls we eventually abandoned
their purication and stapling due to their poor solubility,
which would also translate to problems for pharmacological
characterisation. Stapling of puried or crude 6–9 A–C (see ESI†
for details) was carried out in tBuOH and water (1 : 2 v/v) using
CuSO4$5H2O (1 eq.) and sodium ascorbate (5 eq.) as the in situ
reducing agent. In general, the CuAAC reaction was clean and
went to completion fast (1–3 h) to give stapled peptidomimetics
10–13 A–C that were puried by preparative RP-HPLC to >95%
purity in reasonable yields. Full conversion of linear to stapled
peptidomimetic was monitored by RP-HPLC by spiking the
reaction sample with the linear starting material, and by FT-IR
where the azide stretch (at 2100 cm1) is clearly seen to
disappear aer completion of the stapling reaction (see ESI†).This journal is © The Royal Society of Chemistry 2018
Table 2 Eﬀect of Gs peptidomimetics on the cAMP accumulation induced by isoproterenol (ISO) at the b2-adrenergic receptor (b2AR) in a cell
membrane-based cyclic adenosine monophosphate (cAMP) accumulation assay. Basal cAMP level, maximum eﬃcacy, pEC50(log(EC50)) and
Hill slope of the concentration–response curve of ISO in absence and presence of 100 mM peptidomimetic (10 mM for 8C) were calculated by
non-linear regression using GraphPad Prism. Nb80 was tested at 10 mM. Data are given as mean values of n number of experiments  SEM.
Signiﬁcance level P < 0.05 (*) calculated by statistical analysis with a one-way ANOVA in GraphPad Prism
Peptide Basal level Maximum eﬃcacy pEC50 Hill slope n
Vehicle 0.0  0.0 100.0  0.0 8.64  0.03 0.81  0.05 6
Nb80 1.2  0.7 11.3  0.6* 8.98  0.16 0.88  0.29 3
6A 0.7  1.1 90.8  6.0 8.68  0.04 0.81  0.07 3
6B 2.9  4.2 81.5  4.5 8.48  0.08 0.81  0.12 3
6C 4.6  1.9 89.7  1.5 8.33  0.02 0.83  0.06 3
7A 0.5  1.5 88.8  8.0 8.74  0.01 0.83  0.10 3
7B 4.2  1.8 79.9  2.0* 8.58  0.03 0.84  0.04 3
7C 8.4  4.3 88.1  3.6 8.17  0.11 0.87  0.06 3
8A 1.1  0.7 97.7  5.3 8.67  0.04 0.72  0.02 3
8B 8.8  2.8 77.1  3.9* 8.46  0.15 0.82  0.07 3
8C 3.7  2.3 78.0  5.2* 8.65  0.06 0.71  0.07 3
9A 0.4  0.7 92.7  7.5 8.73  0.08 0.83  0.04 3
9B 3.3  4.6 84.1  2.4 7.05  0.38* 0.89  0.05 3
9C 5.7  2.1 88.1  4.5 8.21  0.33 0.92  0.06 3
10A 3.0  0.4 82.8  3.3 8.67  0.05 0.78  0.03 3
10B 5.0  2.6 80.5  2.2 8.45  0.04 0.72  0.05 3
10C 11.0  4.3 61.0  4.1* 7.87  0.01 0.63  0.06 3
11A 1.4  0.7 90.7  4.6 8.53  0.05 0.74  0.03 3
11B 5.8  3.0 88.0  4.1 8.46  0.07 0.72  0.06 3
11C 1.9  8.4 78.4  2.6* 8.10  0.12 0.85  0.06 3
12A 0.6  0.4 94.5  6.3 8.68  0.03 0.73  0.04 3
12B 2.8  4.0 74.0  3.3* 7.87  0.53 0.88  0.09 3
12C 6.0  2.1 71.7  3.0* 8.52  0.05 0.90  0.06 3
13A 2.4  0.3 90.0  6.4 8.71  0.05 0.85  0.03 3
13B 7.1  5.7 85.1  3.0 7.72  0.30* 0.89  0.04 3
13C 2.3  1.2 82.8  3.8 8.46  0.43 0.80  0.04 3
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View Article OnlineStructural analysis by circular dichroism (CD)
All puried linear and stapled peptides were subjected to
structural analysis by CD. Prior to recording CD spectra, the net
peptide content (NPC) for all peptidomimetics was determined
by quantitative NMR (qNMR, see ESI†).
The CD data in Fig. 3 shows that stapling in general leads to
peptidomimetics with a more helical structure when compared
to the linear counterparts. However, the magnitude of the
induced helicity varies signicantly. While the position of the
staple (A, B or C, Fig. 2) does not have a signicant eﬀect on the
induced helicity, the employed amino acid residues (1–4) that
form the staple have a tremendous eﬀect. Employing residues 1
and 3 clearly increases the helicity of the peptide the most at all
three stapling positions. The use of residues 1 and 4 likewise
shows strong induction of helicity. In contrast, the use of the D-
amino acid 2 in combination with either 3 or 4 lowers the
helical induction markedly.
Pharmacology
Membrane-based cAMP accumulation assay. Initially, the
stapled peptidomimetics (10–13) and their linear precursors (6–
9) were tested for their ability to modulate b2AR agonist-induced
cAMP formation. To allow the peptidomimetics to interact with
the intracellular G protein binding pocket they were tested in
a membrane-based cAMP accumulation assay (see ESI†). In this
setup stimulation of b2AR expressing membranes with variousThis journal is © The Royal Society of Chemistry 2018concentrations of the agonist ()-isoproterenol (ISO) increased
cAMP formation in a concentration-dependent manner (mean
pEC50 ¼ 8.64  0.03). To test the eﬀect of the peptidomimetics
on the ISO-induced cAMP formation, similar ISO concentration
response curves (CRCs) were generated in presence of
a constant concentration of peptidomimetic (100 mM, except for
8C, which was tested at 10 mM due to poor solubility). The cAMP
levels in absence of peptidomimetics were normalised to the
basal (0%) and maximal eﬃcacy (100%) of ISO in presence of
vehicle (DMSO).
All peptidomimetics stapled at position A had little to no
eﬀect on the maximum eﬃcacy of ISO (Table 2). Several of the
peptidomimetics stapled at positions B and C displayed a small
eﬀect on the maximum eﬃcacy of ISO; 7B, 8B, 8C and 11C all
signicantly decreased the maximal eﬃcacy to approximately
80% (Table 2 and Fig. 4). Peptidomimetics 12B and 12C had
a more pronounced eﬀect and inhibited the maximal eﬃcacy to
73% on average. Finally, peptidomimetic 10C aﬀected the
maximal ISO eﬃcacy the most by lowering ISO maximal eﬃcacy
to 61%. With respect to peptidomimetic-induced eﬀects on ISO
potency, 9B and 13B signicantly decreased the potency by 39-
and 8-fold, respectively, but not the eﬃcacy of ISO (Fig. 4). No
signicant eﬀects of the peptidomimetics were observed on the
basal cAMP levels or on the Hill-slope of the tted curves.
To estimate the potency of the most eﬃcacious peptidomi-
metic 10C, increasing concentrations of 10C up to 200 mM, andRSC Adv., 2018, 8, 2219–2228 | 2223
Fig. 4 Representative graphs of themost eﬀective peptidomimetics on the cyclic adenosinemonophosphate (cAMP) production induced by the
full agonist isoproterenol (ISO) at the b2-adrenergic receptor (b2AR). The stapled peptidomimetic 10C inhibited the maximal response of ISO to
61% whereas its linear precursor 6C had no signiﬁcant eﬀect on the ISO-induced cAMP production (A). The linear 7B (B) and stapled pepti-
domimetic 11C (C) inhibited ISO eﬃcacy to a smaller degree (80%) but signiﬁcantly. Their stapled (11B) and linear counterparts (7C) had a minor
(90%) albeit non-statistically signiﬁcant eﬀects. The linear 8B and stapled peptidomimetic 12B pair decreased the maximum response of ISO to
70–80% (D), which is also the case for the linear and stapled pair 8C and 12C (E). The linear 9B and stapled peptidomimetic 13B, decreased the
potency of ISO by 39- and 8-fold, respectively, whereas the eﬃcacy was not aﬀected (F). In presence of ISO corresponding to EC75, the IC50 of
10C was estimated to 55 mM, and the IC50 of Nb80 was estimated to 0.40 mM (G).
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View Article OnlineNb80 as a control were applied in the presence of an ISO
concentration corresponding to EC75. The IC50 of 10C was
estimated to 55 mM whereas the IC50 of Nb80 was estimated to
0.40 mM (Fig. 4).2224 | RSC Adv., 2018, 8, 2219–2228Bimane uorescence shi assay. To further investigate their
pharmacological proles, selected peptidomimetics were tested
in a bimane uorescence shi assay (see ESI†). Labelling of
cysteine residue 265 (C265) located in the lower part of the TM6This journal is © The Royal Society of Chemistry 2018
Fig. 5 Representative bimane emission spectra of isoproterenol (ISO), nanobody 80 (Nb80) and ICI-118,551 (ICI) at the b2-adrenergic receptor
(b2AR). ISO induces an active receptor conformation in a concentration-dependent manner. ISO displays saturating eﬀects at 250 mM and 500
mM (A). Nb80 (5 mM) potentiates the 10 mM ISO-induced bimane-ﬂuorescence response to that of ISO at 250 mM and 500 mM (B). At 10 mM, ICI
prevents the receptor activation induced by 10 mM ISO and has a similar eﬀect on the bimane-ﬂuorescence response alone (C).
Paper RSC Advances
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
9 
Ja
nu
ar
y 
20
18
. D
ow
nl
oa
de
d 
on
 1
0/
24
/2
01
8 
1:
44
:5
8 
PM
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlineof b2AR with a bimane-uorophore allows detection of confor-
mational changes associated with receptor activation.31 Stimu-
lation of puried, C265 uorophore-labelled b2AR with
increasing concentrations of ISO results in a concentration-
dependent decrease in the uorescence intensity (FI) and
a red-shi of the maximum emission wavelength (lmax) of the
bimane-uorophore probe (Fig. 5A). The active receptor
conformation may be further stabilised in the presence of G
protein31 and G protein mimetics such as Nb80.9 Indeed, in
presence of a partial equilibrium shiing ISO concentration (10
mM), Nb80 is capable of decreasing FI and red-shiing lmax
beyond that of ISO (10 mM) or Nb80 (5 mM) alone (Fig. 5B).
Conversely, ICI-118,551 (ICI), an inverse agonist capable of
stabilising an inactive conformation of b2AR, blocks the 10
mM ISO-induced response and also slightly increase FI and
blue-shis lmax on its own (Fig. 5C). Thus, the bimane uo-
rescence shi assay can identify active and inactive-
conformation stabilising ligands of the b2AR.
Based on the results obtained with the cAMP assay, the linear
and cyclic peptidomimetic pairs 6C/10C, 7C/11C, 8C/12C, 8B/
12B and 9B/13B were tested in the bimane assay at 20 mM
(Fig. 6). The peptidomimetics were tested for possible eﬀects on
receptor conformation alone and in the presence of 10 mM ISO,
which allows detection of peptidomimetic-induced active
conformation stabilisation as seen for Nb80. Bimane-
uorescence curves in presence of agonist or peptidomimetic
alone or in combination were normalised to that of the receptor
alone.
Unlike Nb80, none of the tested peptidomimetic were
observed to stabilise an active-like conformation by decreasing
FI and red-shiing lmax on their own or by potentiating the
response beyond that of 10 mM ISO alone. Although there was
a tendency for several peptidomimetics to shi the bimane-
uorescence in the opposite direction (8B, 7–8C and 10–11C),
the peptidomimetics did not aﬀect the response of 10 mM ISO
alone. Interestingly, with the exception of peptidomimetic 8B
only the peptidomimetics stapled at position C closest to the C-
terminal were able to increase FI and blue-shi lmax in a similar
way to that seen for the inverse agonist ICI (Fig. 5C).This journal is © The Royal Society of Chemistry 2018Discussion
As anticipated CD analysis revealed that the stapled peptido-
mimetics generally had a higher helical content than their
linear counterparts and the native Gas 15-mer. The staples
comprised of building blocks 1, 3 and 4 had the highest helical
content, whereas the peptidomimetics stapled with D-amino
acid 2 and alkynes 3 and 4 contained signicantly less helicity.
There was no trend regarding the helical content and the
stapling positions A–C.
The peptidomimetics were evaluated for their ability to
block agonist-induced cAMP formation in cell membranes
overexpressing the b2AR. Stapling the peptidomimetics at
position A was not optimal for blocking cAMP formation by
ISO. Thus, both stapled peptidomimetics 12A–13A and linear
peptidomimetics 8A–9A were essentially inactive, indicating
that this stapling position is not ideal for binding to the
receptor using the present chemistry. Moving the staple
towards the C-terminus (position B and C) was more favour-
able. The linear peptidomimetics 7B and 8B had a slight, yet
signicant eﬀect on the maximal ISO response, lowering the
eﬃcacy to approximately 80%. Stapled peptidomimetic 12B
had a more pronounced eﬀect on the maximum eﬃcacy with
a lowering to 74%. Unexpectedly the 9B/13B pair red-shied
the ISO CRC comparable to that of a competitive antagonist
rather than decreasing the maximal agonist eﬃcacy as would
be expected for a non-competitive antagonist. The linear 8C
and stapled peptidomimetic 11C both lowered the maximum
eﬃcacy of ISO to approximately 80%. On the other hand,
stapled 12C lowered the eﬃcacy to 72%, whereas stapled 10C
lowered the eﬃcacy to approximately 61%. Thus, 10C clearly
gave the most signicant decrease in the maximum eﬃcacy of
ISO. In general, the stapled peptidomimetics gave the highest
reduction in eﬃcacy and a small tendency for peptidomi-
metics with a high helical content to have a greater eﬀect was
observed (ESI Fig. S1†). Thus, stapled peptidomimetics 10C,
12B and 12C with a relatively high helical content were found
to lower the eﬃcacy the most (61–74%). However, the dataRSC Adv., 2018, 8, 2219–2228 | 2225
Fig. 6 Representative bimane emission spectra of selected peptidomimetics with signiﬁcant eﬀects in the cAMP assay. The responses of the
linear and cyclic peptidomimetic pairs 6C/10C, 7C/11C, 8C/12C, 8B/12B and 9B/13Bwere normalised to that of the unliganded b2AR alone (black
solid line). The peptides were tested at 20 mM (n ¼ 2 of measurements in triplicate) in the absence (pink solid line) and the presence (blue solid
line) of ISO 10 mM (grey solid line).
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View Article Onlinealso shows that a high degree of helicity on its own is not
suﬃcient to give a notable reduction in the formation of cAMP
(e.g. stapled peptidomimetic 10B).2226 | RSC Adv., 2018, 8, 2219–2228When tested in the conformational bimane uorescence
shi assay none of the peptidomimetics stabilised an active-like
conformation similar to that of the G protein mimetic Nb80.This journal is © The Royal Society of Chemistry 2018
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View Article OnlineHowever, a small tendency to increase the uorescence inten-
sity (FI) and blue-shi lmax similar to that for the inverse agonist
ICI was seen. The eﬀect was most pronounced for peptidomi-
metics stapled at position C but no correlation between the
degree of helicity and the eﬀect on the FI was observed. It
cannot be excluded that the concentration tested in the bimane
assay was too low to induce a more signicant eﬀect.
One interpretation of the obtained pharmacological data is
that some of the peptidomimetics (e.g. 10C) are capable of
modulating ISO-induced cAMP formation by binding to and
thus overlapping with the intracellular binding site of the G
protein. However, unlike Nb80, none of the peptidomimetics
reported herein stabilise an active-like receptor conformation.
Although only small eﬀects of the peptidomimetics were
observed it does support the idea of developing intracellular
modulators of GPCR signalling derived from hotspot domains
of GPCR interacting proteins (e.g. the C-termini of G proteins).
However, the native C-terminal peptide sequence (GasCT15) that
was employed as a template herein clearly does not provide
potent peptidomimetic analogues despite stapling these in
a helical conformation. Thus, to render this class of ligands of
use for pharmacological and biophysical studies signicant
optimisation is required. It should be noted that the present
study does not provide data that demonstrates that the pepti-
domimetics are binding in the intended G protein binding
pocket. In principle, the peptidomimetics could be engaging
the b2AR elsewhere. Further studies with more potent
analogues will be required to determine the mode of action.
Conclusion
In the present study, a series of peptidomimetics that mimic the
C-terminal a-helix of the Gas protein were synthesised as
potential allosteric modulators of the b2AR. The peptidomi-
metics were characterised pharmacologically in a cAMP accu-
mulation assay and bimane uorescence assay. Several
peptidomimetics inhibited agonist ISO induced cAMP forma-
tion by lowering the maximal eﬃcacy of ISO up to 61%. For the
most potent peptidomimetic 10C the IC50 for blocking ISO
induced cAMP formation was determined to 55 mM. Moreover,
some peptidomimetics could decrease the potency of ISO
signicantly (up to 39-fold). In the bimane uorescence assay
none of the tested peptidomimetics could stabilise an active-
like b2AR conformation. However, we observed a tendency to
shi the bimane assay in the opposite direction for some pep-
tidomimetics. Taken together, the data suggests that some of
the peptidomimetics can compete with the native Gs protein for
the intracellular binding site, but are unable to stabilise an
active-like receptor conformation.
To render the peptidomimetics of use as pharmacological
tool compounds signicant optimisation is required to increase
ligand potency. Likewise, to elucidate the mode of action for
this class of ligands more potent ligands are required. To this
end we are in the process of strengthening ligand–receptor
interactions by substitution with natural and unnatural amino
acids aided by computational design. The results from these
endeavours will be reported elsewhere in due course.This journal is © The Royal Society of Chemistry 2018Conﬂicts of interest
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